Merck to pay Purepac $1.5 mil. in Sinemet CR settlement; generic launch will wait until 2006.
Executive Summary
PUREPAC/MERCK SINEMET CR INFRINGEMENT SUIT SETTLED FOR ABOUT $1.5 MIL.; Purepac will not market a generic version of the Parkinson's therapy until the extended-release formulation patent for Sinemet CR (carbidopa/levodopa) expires in 2006, the company said Feb. 15.